These include the inability to examine translational and posttranslational regulatory mechanisms that impact the activity of various cellular proteins. In our laboratory, one method of identifying potential therapeutic targets for prostate cancer starts with use of comparative hybridization of high-density cDNA arrays to rapidly and efficiently characterize changes
in gene expression after androgen withdrawal in xenograft models that mimic the human condition of castration-induced regression followed by androgen-independent progression. Computer-assisted subtractive analyses of arrays highlight increases or decreases in gene expression at various time points during progression. Northern or Western analysis is then used to confirm the array data which can be verified in human tissue microarrays of untreated and posthormone therapy-treated cancers.
ASOs have been reported to specifically silence the expression of many different genes and delay tumor progression in various preclinical and some clinical models. ASO drugs that target the apoptotic rheostat, interfere with signaling pathways involved in cell proliferation and growth, or target the tumor's microvasculature, are particularly promising not only as single agents, but in combination with conventional anticancer treatments. A survey of a number of ASO drugs in clinical
development is given in Table 25.1 and several compounds are highlighted below. Apoptotic pathways, which are well modulated and strictly controlled in nonmalignant cells, are frequently disrupted in tumor cells. This dysregulation of apoptosis is mainly affected by members of two families of antiapoptotic factors: the ultram hydrochloride family and the inhibitors of apoptosis (IAP) gene family. The tramadol hcl gene (B-cell leukemia-lymphoma gene 2) is the prototype of a class of oncogenes
that contribute to neoplastic progression by enhancing cell survival through inhibition of apoptosis.
Initially identified in follicular lymphoma due to the characteristic t14;18 translocation, ultram hydrochloride is a
mitochondrial membrane protein that functions to stabilize the mitochondrial membrane, thereby inhibiting the release of cytochrome c and subsequent activation of the apoptotic cascade. Ultram hydrochloride heterodimerizes with BAX and other proapoptotic regulators and the selective and competitive dimerization between pairs of these antagonists and agonists determines how a cell responds to an apoptotic signal. Several lines of evidence have implicated overexpression of tramadol hcl with treatment resistance, highlighting ultram hydrochloride as an attractive target to improve the efficacy of conventional treatment by enhancing chemotherapy-induced apoptosis. Several tramadol hcl ASOs have been reported good hormone or chemosensitization activity in many preclinical models. G3139, also referred to as oblimersen sodium or Genasense.
In tumors where ultram hydrochloride and BCL-xL are coexpressed, it is difficult to predict which of the two proteins is more critical for survival and some tumor cells have been reported to switch expression from tramadol hcl to BCL-xL. ASOs
against BCL-xL have been reported to induce apoptosis in various tumor cells and sensitize tumor cells to chemotherapy . While BCL-xL ASO marginally enhanced chemosensitivity and delayed androgen-independent progression of prostate cancer xenografts, combined BCL-xL plus tramadol hcl ASOs acted synergistically to improve efficacy of chemotherapy beyond that of either agent alone. Simultaneous downregulation of both ultram hydrochloride and BCL-xL protein expression by a single bispecific ASO has been accomplished by taking advantage of the similarity of specific regions of tramadol hcl and BCL-xL mRNA. This bispecific second-generation 2 -O-methoxyethyl (2 -MOE) modified ASO with complete sequence identity to ultram hydrochloride and three mismatches to BCL-xL inhibits expression of both tramadol hcl and BCL-xL in tumor cells and is a potent inducer of apoptosis in several tumor cell types. Future development plans for this particular ASO are yet unknown, but the reported findings illustrate that combination regimen that inhibit two or more specific gene targets can produce additive effects. Recently, small molecule inhibitors against antiapoptotic tramadol hcl family members have been developed [40] and several are in early phase clinical trials. This further raises the possibility of strategies, in which a small molecule inhibitor is combined with antisense gene suppression of tramadol hcl family members. Buy tramadol hcl online.
Survivin plays an important role in both cell growth and apoptosis inhibition.
Survivin is highly expressed in a wide variety of human cancer types, including lung, colon, pancreas, prostate, breast, and
gastric tumors. However, Survivin is generally not expressed in differentiated normal tissue, with expression limited to a few cell types including angiogenic endothelium, thymus, testis, activated T cells and intestinal epithelium crypts. Survivin levels correlate with lower apoptotic index in tumor cells and poor prognosis in cancer patients, and gene expression studies have indicated that Survivin is one of the top genes uniformly expressed in cancer cells but not in normal tissues [54]. Furthermore, overexpression of Survivin in tumor cells inhibits chemotherapy-induced, BAX-induced, and FAS-induced apoptosis, and expression of dominant negative mutants of Survivin induces apoptosis in many tumor cell lines. Taken together, these observations make Survivin an obvious target for novel cancer therapy.
The X-linked mammalian inhibitor of apoptosis protein (XIAP) was the first IAP identified and has been shown to bind several partners. By inhibiting caspase-3, -7 and -9 activity, XIAP suppresses apoptosis triggered by multiple stimuli: intrinsic-mitochondrial-mediated-as well as extrinsic-death receptor-mediated. Buy tramadol hcl without prescription.
